| Autor: |
Malfatti, Michael A., Enright, Heather A., McCloy, Summer, Ubick, Esther A., Kuhn, Edward, Subramanian, Alagu, Lao, Victoria Hio Leong, Lam, Doris, Be, Nicholas A., Hok, Saphon, Lau, Edmond Y., Kaseman, Derrick C., Mayer, Brian P., Valdez, Carlos A. |
| Zdroj: |
ACS Central Science; 20240101, Issue: Preprints |
| Abstrakt: |
Subetadex-α-methyl (SBX-Me), a modified, polyanionic cyclodextrin scaffold, has been evaluated for its utilization as a medical countermeasure (MCM) to neutralize the effects of fentanyl and related opioids. Initial in vitrotoxicity assays demonstrate that SBX-Me has a nontoxic profile, comparable to the FDA-approved cyclodextrin-based drug Sugammadex. Pharmacokinetic analysis showed rapid clearance of SBX-Me with an elimination half-life of ∼7.4 h and little accumulation in major organs. SBX-Me was also evaluated for its ability to counteract the effects of fentanyl, carfentanil, and remifentanil in rats. Recovery times in rats exposed to sublethal fentanyl doses were found to be shorter when treated with SBX-Me after opioid exposure. The recovery times were reduced from ∼35 to ∼17 min for fentanyl, ∼172 to ∼59 min for carfentanil, and ∼18 to ∼12 min for remifentanil. SBX-Me increased the elimination half-life for fentanyl and remifentanil from 5.37 to 6.42 h and 8.24 to 9.74 h, respectively. These data support SBX-Me as a solid platform from which further research can be launched for the development of a MCM against the effects of fentanyl and its analogs. Furthermore, the data suggests that SBX-Me and other analogs are attractive candidates as broad spectrum opioids targeting MCMs. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
